129 related articles for article (PubMed ID: 30366277)
1. Regulatory T cells demonstrate significantly increased functions following stimulation with IL-2 in a Tim-3-dependent manner in intracranial aneurysms.
Zhang HF; Liang GB; Zhao MG; Zhao GF; Luo YH
Int Immunopharmacol; 2018 Dec; 65():342-347. PubMed ID: 30366277
[TBL] [Abstract][Full Text] [Related]
2. Patients with intracranial aneurysms presented defects in regulatory T cells, which were associated with impairment in Tim-3 upregulation.
Zhang HF; Liang GB; Zhao MG; Zhao GF; Luo YH
Int Immunopharmacol; 2018 Nov; 64():350-355. PubMed ID: 30243071
[TBL] [Abstract][Full Text] [Related]
3. Soluble galectin 9 potently enhanced regulatory T-cell formation, a pathway impaired in patients with intracranial aneurysm.
Zhao MG; Liang GB; Zhang HF; Zhao GF; Luo YH
Clin Exp Pharmacol Physiol; 2018 Nov; 45(11):1206-1212. PubMed ID: 29978574
[TBL] [Abstract][Full Text] [Related]
4. Defective Treg response in acute kidney injury was caused by a reduction in TIM-3
Dong Q; Cai C; Gao F; Chen P; Gong W; Shen M
Immunol Invest; 2019 Jan; 48(1):27-38. PubMed ID: 29985717
[TBL] [Abstract][Full Text] [Related]
5. Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells.
Gautron AS; Dominguez-Villar M; de Marcken M; Hafler DA
Eur J Immunol; 2014 Sep; 44(9):2703-2711. PubMed ID: 24838857
[TBL] [Abstract][Full Text] [Related]
6. Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in β-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype.
Shokrgozar N; Karimi M; Golmoghaddam H; Rezaei N; Moayed V; Sharifzadeh S; Arandi N
Ann Hematol; 2021 Oct; 100(10):2463-2469. PubMed ID: 34324022
[TBL] [Abstract][Full Text] [Related]
7. Overrepresentation of highly functional T regulatory cells in patients with nonfunctioning pituitary adenoma.
Han S; Ma E; Jiang W; Lu Y; Sun X; Feng S
Hum Immunol; 2020 Jun; 81(6):314-319. PubMed ID: 32279926
[TBL] [Abstract][Full Text] [Related]
8. Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression.
Yamaguchi T; Kishi A; Osaki M; Morikawa H; Prieto-Martin P; Wing K; Saito T; Sakaguchi S
Proc Natl Acad Sci U S A; 2013 Jun; 110(23):E2116-25. PubMed ID: 23690575
[TBL] [Abstract][Full Text] [Related]
9. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.
Asano T; Meguri Y; Yoshioka T; Kishi Y; Iwamoto M; Nakamura M; Sando Y; Yagita H; Koreth J; Kim HT; Alyea EP; Armand P; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Maeda Y; Tanimoto M; Ritz J; Matsuoka KI
Blood; 2017 Apr; 129(15):2186-2197. PubMed ID: 28151427
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo.
Durham NM; Nirschl CJ; Jackson CM; Elias J; Kochel CM; Anders RA; Drake CG
PLoS One; 2014; 9(11):e109080. PubMed ID: 25372844
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of LAG3 and TIM3 identifies a potent Treg population that suppresses macrophage functions in colorectal cancer patients.
Ma Q; Liu J; Wu G; Teng M; Wang S; Cui M; Li Y
Clin Exp Pharmacol Physiol; 2018 Oct; 45(10):1002-1009. PubMed ID: 29905955
[TBL] [Abstract][Full Text] [Related]
12. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment.
Banerjee H; Nieves-Rosado H; Kulkarni A; Murter B; McGrath KV; Chandran UR; Chang A; Szymczak-Workman AL; Vujanovic L; Delgoffe GM; Ferris RL; Kane LP
Cell Rep; 2021 Sep; 36(11):109699. PubMed ID: 34525351
[TBL] [Abstract][Full Text] [Related]
13. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
14. Blockage of TIM-3 relieves lupus nephritis by expanding Treg cells and promoting their suppressive capacity in MRL/lpr mice.
Gao YF; Lu YY; Fan XZ; Wang YH; Tian JH; Saed YA; Li RS; Zhou XS
Int Immunopharmacol; 2022 Sep; 110():108971. PubMed ID: 35777268
[TBL] [Abstract][Full Text] [Related]
15. Activated Galectin-9/Tim3 promotes Treg and suppresses Th1 effector function in chronic lymphocytic leukemia.
Pang N; Alimu X; Chen R; Muhashi M; Ma J; Chen G; Zhao F; Wang L; Qu J; Ding J
FASEB J; 2021 Jul; 35(7):e21556. PubMed ID: 34137463
[TBL] [Abstract][Full Text] [Related]
16. Granzyme B-expressing treg cells are enriched in colorectal cancer and present the potential to eliminate autologous T conventional cells.
Sun B; Liu M; Cui M; Li T
Immunol Lett; 2020 Jan; 217():7-14. PubMed ID: 31669380
[TBL] [Abstract][Full Text] [Related]
17. Dysfunction of regulatory T cells in patients with ankylosing spondylitis is associated with a loss of Tim-3.
Wang M; Liu C; Bond A; Yang J; Zhou X; Wang J; Ji B
Int Immunopharmacol; 2018 Jun; 59():53-60. PubMed ID: 29625390
[TBL] [Abstract][Full Text] [Related]
18. Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: roles of IL-17 and TNF-α.
Gradolatto A; Nazzal D; Truffault F; Bismuth J; Fadel E; Foti M; Berrih-Aknin S
J Autoimmun; 2014 Aug; 52():53-63. PubMed ID: 24405842
[TBL] [Abstract][Full Text] [Related]
19. The Tim-3/galectin-9 pathway involves in the homeostasis of hepatic Tregs in a mouse model of concanavalin A-induced hepatitis.
Ju Y; Shang X; Liu Z; Zhang J; Li Y; Shen Y; Liu Y; Liu C; Liu B; Xu L; Wang Y; Zhang B; Zou J
Mol Immunol; 2014 Mar; 58(1):85-91. PubMed ID: 24333756
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of T cell immunoglobulin and mucin protein 3 in the pathogenesis of intracranial aneurysm.
Zhang HF; Zhao MG; Liang GB; Yu CY; Li ZQ; Gao X
Inflammation; 2015 Feb; 38(1):368-74. PubMed ID: 25342285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
